A Phase 3 interventional study of adalimumab and placebo in Ankylosing Spondylitis, sponsored by Abbott. Completed at 9 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-12-01.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing adalimumab in Spondylitis, Ankylosing — 2 open to participants now, 3 under way, none of them phase 3. Adalimumab · Spondylitis, Ankylosing.
Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 7th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 98 are open to participants now.
Browse Spondylitis, Ankylosing studies →2 of the 19 studies testing adalimumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
The Affiliated Hospital Of Guizhou Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 8
First in 2003; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 344 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 80 across the 19 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 19 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 7 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
1 of the studies testing adalimumab in Spondylitis, Ankylosing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833112The Affiliated Hospital Of Guizhou Medical UniversityInterleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory drugs (NSAIDs)
Adults with active ankylosing spondylitis (AS) were randomized in a 2:1 ratio to receive treatment with adalimumab 40 mg every other week (eow) or matching placebo, given subcutaneously (SC), in the 12-week double-blind (DB) phase. Randomized participants received one SC injection of the appropriate DB study medication (adalimumab 40 mg or matching placebo) at Week 0 and then eow until Week 10. Participants who completed the DB phase could enter the 12-week open-label (OL) phase, during which all participants received treatment with adalimumab 40 mg eow, starting at Weeks 12 through 22. No study drug was administered or injected at the final study visit (Week 24). A follow-up visit occurred 70 days after the last dose of study drug (in DB or OL phases) to obtain information on any ongoing or new adverse events (AEs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has active AS, as defined by fulfillment of at least 2 of the following 3 conditions at both Screening and Baseline visits:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
Biological: adalimumab · Other: placebo
Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
Biological: adalimumab
Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
Also known as: ABT-D2E7, Humira
Prefilled syringe, matching placebo administered subcutaneously every other week
Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria
ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).
Time frame: Week 12
Number of Participants Meeting the ASAS20 Response Criteria
ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).
Time frame: Week 24
Number of Participants Meeting the ASAS40 Response Criteria
An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).
Time frame: Week 12
Number of Participants Meeting the ASAS40 Response Criteria
An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).
Time frame: Week 24
Number of Participants Meeting the ASAS5/6 Response Criteria
An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \[BASMI\]); and acute phase reactant (high-sensitivity C-reactive protein).
Time frame: Week 12
Number of Participants Meeting the ASAS5/6 Response Criteria
An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \[BASMI\]); and acute phase reactant (high-sensitivity C-reactive protein).
Time frame: Week 24
Number of Participants With ASAS Partial Remission
Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).
Time frame: Week 12
Number of Participants With ASAS Partial Remission
Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).
Time frame: Week 24
Change From Baseline in Patient Global Assessment of Disease Activity
Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).
Time frame: Baseline and Week 12
Change From Baseline in Patient Global Assessment of Disease Activity
Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).
Time frame: Baseline and Week 24
Change From Baseline in Total Back Pain Score
Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).
Time frame: Baseline and Week 12
Change From Baseline in Total Back Pain Score
Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).
Time frame: Baseline and Week 24
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.
Time frame: Baseline and Week 12
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.
Time frame: Baseline and Week 24
Change From Baseline in Inflammation Score
The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: "How would you describe the overall level of morning stiffness you have had from the time you wake up?", with response ranging from none to very severe; and "How long does your morning stiffness last from the time you wake up?", with response ranging from 0 hours to 2 or more hours.
Time frame: Baseline and Week 12
Change From Baseline in Inflammation Score
The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: "How would you describe the overall level of morning stiffness you have had from the time you wake up?", with response ranging from none to very severe; and "How long does your morning stiffness last from the time you wake up?", with response ranging from 0 hours to 2 or more hours.
Time frame: Baseline and Week 24
Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria
A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from "none" to "very severe" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).
Time frame: Week 12
Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria
A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from "none" to "very severe" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).
Time frame: Week 24
Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)
Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.
Time frame: Baseline and Week 12
Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)
Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.
Time frame: Baseline and Week 24
Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score
The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.
Time frame: Baseline and Week 12
Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score
The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.
Time frame: Baseline and Week 24
| Milestone | Adalimumab | Placebo |
|---|---|---|
| Started | 229 | 115 |
| Completed | 224 | 113 |
| Not completed | 5 | 2 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Poor subject compliance | 0 | 1 |
| Milestone | Adalimumab | Placebo |
|---|---|---|
| Started | 224 | 113 |
| Completed | 221 | 111 |
| Not completed | 3 | 2 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria | 154 | 35 |
ASAS20 responder had improvement of 20% or more and absolute improvement of at least 10 units (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the following 4 domains, with absence of deterioration (change for worse of at least 20% and net worsening of at least 10 units) in the potential remaining domain: Patient's Global Assessment of Disease Activity; Total Back Pain visual analog scale (VAS); Bath Ankylosing Spondylitis Functional Index (BASFI); and Inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants Meeting the ASAS20 Response Criteria | 180 | 85 |
An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants Meeting the ASAS40 Response Criteria | 102 | 11 |
An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants Meeting the ASAS40 Response Criteria | 134 | 63 |
An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \[BASMI\]); and acute phase reactant (high-sensitivity C-reactive protein).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants Meeting the ASAS5/6 Response Criteria | 128 | 14 |
An ASAS5/6 responder had an improvement from Baseline of 20% or more in 5 of the following 6 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores); spinal mobility (lateral lumbar flexion from Bath Ankylosing Spondylitis Metrology Index \[BASMI\]); and acute phase reactant (high-sensitivity C-reactive protein).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants Meeting the ASAS5/6 Response Criteria | 150 | 69 |
Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants With ASAS Partial Remission | 50 | 4 |
Participants were classified as having achieved ASAS partial remission if they had a value of less than 20 on a scale from 0 (normal/none) to 100 (most severe) in each of 4 domains: Patient's Global Assessment of Disease Activity; pain as measured by the Total Back Pain visual analog scale (VAS); function as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI); and inflammation (mean of 2 morning stiffness-related Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] scores).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants With ASAS Partial Remission | 85 | 33 |
Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).
| millimeters | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in Patient Global Assessment of Disease Activity | -28.8 ± 24.16 | -11.7 ± 21.77 |
Participants assessed their disease activity during the preceding week using a 100 millimeter (mm) visual analog scale, with responses ranging from no activity (0) to severe activity (100).
| millimeters | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in Patient Global Assessment of Disease Activity | -37.8 ± 24.47 | -35.5 ± 25.03 |
Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).
| millimeters | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in Total Back Pain Score | -32.0 ± 23.55 | -13.7 ± 22.88 |
Participants assessed their total back pain within the preceding week using a total back pain 100 mm visual analog scale, with responses ranging from no pain (0) to most severe pain (100).
| millimeters | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in Total Back Pain Score | -42.1 ± 23.29 | -37.8 ± 24.20 |
Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.
| units on a scale | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score | -17.5 ± 20.18 | -4.7 ± 16.40 |
Participants assessed their ability to perform 10 selected activities (e.g., putting on socks or tights without help or aids, bending forward from the waist to pick up a pen from the floor without an aid) during the preceding week. Responses ranged from 0 (easy) to 100 (impossible). The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 100.
| units on a scale | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score | -23.2 ± 21.03 | -20.9 ± 21.51 |
The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: "How would you describe the overall level of morning stiffness you have had from the time you wake up?", with response ranging from none to very severe; and "How long does your morning stiffness last from the time you wake up?", with response ranging from 0 hours to 2 or more hours.
| centimeters | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in Inflammation Score | -2.9 ± 2.01 | -1.5 ± 2.16 |
The Inflammation score is the mean of the 10-cm visual analog scale scores from the 2 morning stiffness-related BASDAI questions: "How would you describe the overall level of morning stiffness you have had from the time you wake up?", with response ranging from none to very severe; and "How long does your morning stiffness last from the time you wake up?", with response ranging from 0 hours to 2 or more hours.
| centimeters | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in Inflammation Score | -3.6 ± 2.21 | -3.6 ± 2.24 |
A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from "none" to "very severe" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria | 114 | 19 |
A BASDAI50 responder had at least a 50% improvement from Baseline in BASDAI score. In the BASDAI, participants use a 10-centimeter visual analog scale to answer 6 questions pertaining to symptoms experienced in the preceding week (e.g., How would you describe the overall level of fatigue/tiredness you have experienced? How long does your morning stiffness last from the time you wake up?) Responses range from "none" to "very severe" or from 0 hours to 2 or more hours for morning stiffness. The score is calculated as 0.2 (Q1 + Q2 + Q3 + Q4 + Q5/2 + Q6/2).
| participants | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Number of Participants Meeting the Bath Ankylosing Spondyloarthritis Disease Activity Index (BASDAI) BASDAI50 Response Criteria | 156 | 71 |
Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.
| milligrams/liter | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP) | -17.8 ± 23.76 | -4.2 ± 21.23 |
Elevation of hs-CRP is a nonspecific marker of inflammation. Values above 5 milligrams/liter (mg/L) were considered abnormally high. Decrease in level of hs-CRP indicates reduction in inflammation.
| milligrams/liter | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP) | -18.2 ± 24.27 | -20.1 ± 30.63 |
The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.
| units on a scale | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score | 6.6 ± 6.43 | 4.0 ± 6.31 |
The SF-36 questionnaire, version 2, consists of 36 general health questions with 2 components, physical and mental. For each component, a transformed summary score is calculated using 8 sub-domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores range from 0 to 100. Higher scores indicate a better health state.
| units on a scale | Adalimumab/Adalimumab | Placebo/Adalimumab |
|---|---|---|
| Change From Baseline in 36-item Short Form Questionnaire Version 2 (SF-36v2) Physical Component Summary Score | 8.6 ± 7.44 | 9.2 ± 7.25 |
Collected over All adverse events reported from the time of first study drug administration until 70 days following discontinuation of study drug administration were collected, for a maximum reporting period of 32 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab (Period 1) | — | 1/229 (0.4%) | 55/229 (24%) |
| Placebo (Period 1) | — | 1/115 (0.9%) | 16/115 (13.9%) |
| Adalimumab/Adalimumab (Period 2) | — | 3/224 (1.3%) | 32/224 (14.3%) |
| Placebo/Adalimumab (Period 2) | — | 1/113 (0.9%) | 22/113 (19.5%) |
| Event | Adalimumab (Period 1) | Placebo (Period 1) | Adalimumab/Adalimumab (Period 2) | Placebo/Adalimumab (Period 2) |
|---|---|---|---|---|
| Hepatitis viralInfections and infestations | 0/229 | 0/115 | 0/224 | 1/113 |
| Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/229 | 1/115 | 0/224 | 0/113 |
| Intraductal papilloma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/229 | 1/115 | 0/224 | 0/113 |
| Peritoneal tuberculosisInfections and infestations | 0/229 | 0/115 | 1/224 | 0/113 |
| Pulmonary tuberculosisInfections and infestations | 0/229 | 0/115 | 1/224 | 0/113 |
| Tuberculosis pleurisyInfections and infestations | 0/229 | 0/115 | 1/224 | 0/113 |
| ConcussionInjury, poisoning and procedural complications | 0/229 | 0/115 | 1/224 | 0/113 |
| ContusionInjury, poisoning and procedural complications | 0/229 | 0/115 | 1/224 | 0/113 |
| Skin lacerationInjury, poisoning and procedural complications | 0/229 | 0/115 | 1/224 | 0/113 |
| Abortion inducedSurgical and medical procedures | 0/229 | 0/115 | 1/224 | 0/113 |
| Event | Adalimumab (Period 1) | Placebo (Period 1) | Adalimumab/Adalimumab (Period 2) | Placebo/Adalimumab (Period 2) |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 26/229 | 2/115 | 11/224 | 13/113 |
| Aspartate aminotransferase increasedInvestigations | 20/229 | 1/115 | 6/224 | 9/113 |
| Upper respiratory tract infectionInfections and infestations | 13/229 | 9/115 | 13/224 | 8/113 |
| White blood cell count decreasedInvestigations | 6/229 | 2/115 | 2/224 | 1/113 |
| Blood bilirubin increasedInvestigations | 0/229 | 0/115 | 4/224 | 0/113 |
| Platelet count decreasedInvestigations | 2/229 | 0/115 | 4/224 | 0/113 |
| Injection site swellingGeneral disorders | 1/229 | 0/115 | 0/224 | 2/113 |
| Blood alkaline phosphatase increasedInvestigations | 3/229 | 0/115 | 0/224 | 2/113 |
| Blood triglycerides increasedInvestigations | 3/229 | 1/115 | 2/224 | 2/113 |
| Injection site erythemaGeneral disorders | 4/229 | 0/115 | 0/224 | 1/113 |
| Age Continuous(years) | Adalimumab | Placebo | Total |
|---|---|---|---|
| Mean | 30.1 ± 8.73 | 29.6 ± 7.49 | 29.9 ± 8.33 |
| Sex: Female, Male(Participants) | Adalimumab | Placebo | Total |
|---|---|---|---|
| Female | 44 | 20 | 64 |
| Male | 185 | 95 | 280 |
| Region of Enrollment(participants) | Adalimumab | Placebo | Total |
|---|---|---|---|
| China | 229 | 115 | 344 |
The record gives a start of Jan 2010, a primary completion of Sep 2010 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab